797 related articles for article (PubMed ID: 36275672)
1. Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients.
Becker M; Cossmann A; Lürken K; Junker D; Gruber J; Juengling J; Ramos GM; Beigel A; Wrenger E; Lonnemann G; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Strengert M; Dulovic A; Behrens GMN
Front Immunol; 2022; 13():1004045. PubMed ID: 36275672
[TBL] [Abstract][Full Text] [Related]
2. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
[TBL] [Abstract][Full Text] [Related]
3. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
4. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
7. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
8. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
[TBL] [Abstract][Full Text] [Related]
9. Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination.
Dulovic A; Strengert M; Ramos GM; Becker M; Griesbaum J; Junker D; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
Emerg Infect Dis; 2022 Apr; 28(4):743-750. PubMed ID: 35203113
[TBL] [Abstract][Full Text] [Related]
10. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
[TBL] [Abstract][Full Text] [Related]
11. mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.
Longet S; Hargreaves A; Healy S; Brown R; Hornsby HR; Meardon N; Tipton T; Barnes E; Dunachie S; Duncan CJA; Klenerman P; Richter A; Turtle L; de Silva TI; Carroll MW
Front Immunol; 2022; 13():953949. PubMed ID: 36159846
[TBL] [Abstract][Full Text] [Related]
12. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F
Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364
[TBL] [Abstract][Full Text] [Related]
13. BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19.
Kaznadzey A; Tutukina M; Bessonova T; Kireeva M; Mazo I
Front Immunol; 2022; 13():797918. PubMed ID: 35493476
[TBL] [Abstract][Full Text] [Related]
14. Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2.
Rammauro F; Carrión F; Olivero-Deibe N; Fló M; Ferreira A; Pritsch O; Bianchi S
Vaccine; 2022 Aug; 40(35):5189-5196. PubMed ID: 35907676
[TBL] [Abstract][Full Text] [Related]
15. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
[TBL] [Abstract][Full Text] [Related]
16. Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection.
Bingula R; Chabrolles H; Bonnet B; Archimbaud C; Brebion A; Cosme J; Ollier A; Dutheil F; Junda M; Mirand A; Regagnon C; Vidal M; Henquell C; Evrard B
Emerg Microbes Infect; 2023 Dec; 12(1):2184176. PubMed ID: 36848040
[TBL] [Abstract][Full Text] [Related]
17. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
Tut G; Lancaster T; Krutikov M; Sylla P; Bone D; Kaur N; Spalkova E; Bentley C; Amin U; Jadir AT; Hulme S; Butler MS; Ayodele M; Bruton R; Shrotri M; Azmi B; Fuller C; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
Lancet Healthy Longev; 2021 Sep; 2(9):e544-e553. PubMed ID: 34430954
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.
Benning L; Klein K; Morath C; Bartenschlager M; Kim H; Buylaert M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Schaier M; Speer C
Front Immunol; 2022; 13():840136. PubMed ID: 35309320
[TBL] [Abstract][Full Text] [Related]
20. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.
Hielscher F; Schmidt T; Klemis V; Wilhelm A; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Sester U; Widera M; Sester M
J Clin Virol; 2022 Dec; 157():105321. PubMed ID: 36279695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
